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ttp://dx.doi.org/10.1016/j.ajpath.2012.12.003These studies used bi-transgenic Clara cell secretory protein (CCSP)/IL-1b mice that conditionally over-
express IL-1b in Clara cells to determine whether IL-1b can promote angiogenesis and lymphangiogenesis
in airways. Doxycycline treatment induced rapid, abundant, and reversible IL-1b production, inﬂux of
neutrophils and macrophages, and conspicuous and persistent lymphangiogenesis, but surprisingly no
angiogenesis. Gene proﬁling showed many up-regulated genes, including chemokines (Cxcl1, Ccl7),
cytokines (tumor necrosis factor a, IL-1b, and lymphotoxin-b), and leukocyte genes (S100A9, Aif1/Iba1).
Newly formed lymphatics persisted after IL-1b overexpression was stopped. Further studies examined how
IL1R1 receptor activation by IL-1b induced lymphangiogenesis. Inactivation of vascular endothelial
growth factor (VEGF)-C and VEGF-D by adeno-associated viral vector-mediated soluble VEGFR-3 (VEGF-C/D
Trap) completely blocked lymphangiogenesis, showing its dependence on VEGFR-3 ligands. Consistent
with this mechanism, VEGF-C immunoreactivity was present in some Aif1/Iba1-immunoreactive macro-
phages. Because neutrophils contribute to IL-1beinduced lung remodeling in newbornmice, we examined
their potential role in lymphangiogenesis. Triple-transgenic CCSP/IL-1b/CXCR2/ mice had the usual
IL-1b-mediated lymphangiogenesis but no neutrophil recruitment, suggesting that neutrophils are not
essential. IL1R1 immunoreactivity was found on some epithelial basal cells and neuroendocrine cells,
suggesting that these cells are targets of IL-1b, but was not detected on lymphatics, blood vessels, or
leukocytes. We conclude that lymphangiogenesis triggered by IL-1b overexpression in mouse airways is
driven by VEGF-C/D from macrophages, but not neutrophils, recruited by chemokines from epithelial cells
that express IL1R1. (Am J Pathol 2013, 182: 1434e1447; http://dx.doi.org/10.1016/j.ajpath.2012.12.003)See next page for support information.IL-1b is a key inﬂammatory cytokine found in many path-
ologic conditions and is responsible for triggering multiple
downstream inﬂammatory pathways.1 Inhibiting IL-1 sig-
naling by neutralizing antibodies or by blocking IL1R1
receptors is effective in treating inﬂammation in numerous
pathologic conditions.2 However, IL-1b can be a two-edgedstigative Pathology.
.sword. Depending on the context, IL-1b is responsible for
deleterious effects by amplifying inﬂammation and also for
protective effects, for example, by activating the immune
system during infection.3
IL-1b Induces LymphangiogenesisIL-1b has a main role in the remodeling of many tissues,
including the airways and lungs. Overexpression of IL-1b
in adult mouse airways and lungs results in pulmonary
inﬂammation and the recruitment of inﬂammatory cells,
including neutrophils, enlargement of distal airspaces, and
the induction of mucous metaplasia and airway ﬁbrosis.4 In
neonatal mice, overexpression of IL-1b results in the
disruption of lung development characteristic of broncho-
pulmonary dysplasia,5,6 and this effect is mediated in part by
integrins.7,8 Furthermore, in addition to its known effects on
remodeling of many tissue types, IL-1b has been reported to
induce angiogenesis in several experimental models and in
human diseases, including the eye, arthritic joints, and
tumors, mediated in part by recruitment of leukocytes that
release other inﬂammatory mediators.9e14
Blood vessels and lymphatics of airways show a wide
repertoire of responses to different inﬂammatory stimuli.
Various patterns of blood vessel enlargement and angiogenic
sprouting are found in mice with chronic airway inﬂamma-
tion.15e17 For the most part, the cellular and molecular medi-
ators that drive vascular changes are still poorlyunderstood, but
numerous cytokines and chemokines, including IL-1b, are up-
regulated inMycoplasma pulmonis infection.17e20 M. pulmo-
nis-infected mice also show profound lymphangiogenesis,
mediated by vascular endothelial growth factor receptor
(VEGFR)-3 signaling.21 Because IL-1b can activate NF-kB
pathways to up-regulate vascular endothelial growth factor
(VEGF)-C and -D, ligands forVEGFR-3,22,23 IL-1b could also
be a candidate for driving lymphangiogenesis. IL-1b is also
known to up-regulateVEGF-C in vitro, a VEGFR-3 ligand that
can drive lymphangiogenesis.24 However, it has been difﬁcult
to dissect the effects of individual cytokines in bacterial
infection, and the effects of IL-1b alone in airways have not
been examined.
With this background, we took advantage of bi-transgenic
(CCSP/IL-1b) mice in which IL-1b is overexpressed in
airways by the rat Clara cell secretory protein (CCSP)
promoter in a doxycycline (Dox)-inducible fashion.4 This
model permitted us to study the effects of overexpression of
IL-1b alone on lymphangiogenesis and angiogenesis.
The goal of this study was to determine whether selective
overexpression of IL-1b in adult mouse airways would
induce growth or remodeling of blood vessels or lymphatic
vessels and to determine the involved cells and molecules.
We also sought to learn if vessel remodeling persisted after
IL-1b was turned off and if VEGFR-3 signaling drove the
lymphangiogenesis. To approach these issues, we stained
blood vessels and lymphatics immunohistochemically inSupported in part by National Heart, Lung, and Blood Institute grants HL-
24136 andHL-59157 (D.M.),National Cancer Institute grant CA-82923 (D.M.),
and the Leducq Foundation (D.M.), the Academy of Finland Collaborative
Research Consortium grant 262976 (K.A.), European Research Council (TX-
Factors, grant 268804 to K.A.), Swedish Medical Research Council (K.B.),
Swedish Heart and Lung Foundation (K.B.), the Frimurare Barnhus Foundation
(K.B.), the Swedish Government Grants for Medical Research (K.B.), and the
Queen Silvia Children’s Hospital Research Foundation (K.B.).
The American Journal of Pathology - ajp.amjpathol.orgwhole mounts of tracheas from CCSP/IL-1b mice treated
with Dox. We also used immunohistochemistry to identify
airway cells that stained for IL1R1. Because IL-1b induced
leukocyte inﬂux, including abundant neutrophils, we tested
whether neutrophils were essential for the effects of IL-1b
on lymphatic vessels by examining lymphangiogenesis in
CXCR2/ mice crossed to CCSP/IL-1b mice.
We found that overexpression of IL-1b in mouse airways
produced neutrophil and macrophage inﬂux, expression of
inﬂammatory cytokines and chemokines, and long-lasting
lymphangiogenesis, but not angiogenesis. IL1R1 receptors
were abundant on epithelial basal cells andneuroendocrine cells,
but not on lymphatics. Inactivation of VEGFR-3 ligands by
soluble VEGFR-3 (VEGF-C/D Trap) from an adeno-associated
viral (AAV) vector completely blocked the lymphangiogenesis,
indicative of the necessity of VEGFR-3 ligands, VEGF-C and/
or VEGF-D. VEGF-C immunoreactivity was present in some
recruited macrophages, but the lymphangiogenesis did not
require the inﬂux of neutrophils.
Materials and Methods
Mice
We used 8- to 10-week-old bi-transgenic mice with CCSP
reverse tetracycline transactivator (rtTA) and tetracycline
operator (tetO)-hIL-1 (abbreviated to CCSP/IL-1b) as previ-
ously described.4 The mice express human (h) IL-1 in the
presence of Dox. Because expression of the rtTA gene or
protein can have immunologic effects in mice,25,26 single-
transgenic CCSP-rtTA littermates (The Jackson Laboratory,
Bar Harbor, ME; strain no. 006222, line 127) were used as
controls. For some experiments, we generated triple-transgenic
CCSP/IL-1b/CXCR2/ mice that can be induced to over-
express IL-1bbut lackCXCR2 receptors byback-crossingmice
that lacked CXCR2 receptors (The Jackson Laboratory; strain
no. 002724,28) into theFVB/Nbackground for nine generations
and then crossing with CCSP/IL-1b mice.29 To assess the
distribution of Clara cells in tracheas, we crossedCCSPmice to
(tetO)-nuclear-targetedgreenﬂuorescent protein (GFP) reporter
mice (The Jackson Laboratory; strain no. 00510430). All mice
were genotyped by PCR analysis of genomic tail DNAwith the
use of primers speciﬁc for transgene constructs.4 Mice were
housed in pathogen-free conditions and had free access to food
and water. For experiments, mice were anesthetized with
a mixture of ketamine, xylazine, and acepromazine injected
intraperitoneally and were sacriﬁced by transection of abdom-
inal vessels or by perfusion ofﬁxative. The InstitutionalAnimal
Care and Use Committees of the University of Gothenburg,
University of Helsinki, and the University of California at San
Francisco approved all experimental procedures.
Doxycycline Treatment
To induce IL-1b overexpression, transgenic mice received
Dox (Sigma-Aldrich, St Louis, MO) at 0.5 mg/mL in1435
Baluk et aldrinking water. In some experiments, we turned off gene
expression by removing the Dox water and substituting with
normal water.
Treatment with AAV Vector-Mediated Soluble VEGFR-3
To blockVEGFR-3 signaling, CCSP/IL-1bmicewere treated
with a recombinant AAV-derived soluble VEGFR-3 receptor
(VEGF-C/D Trap) that absorbs VEGF-C and VEGF-D, the
ligands for VEGFR-3. Control mice received AAVs that
encoded the inactive domains four to seven of VEGFR-3-Ig.
The AAVs (serotype 9) were produced and administered as
described previously.31,32 In brief, 150 mL of AAV particles
(at a concentration of approximately 4.5 109 virus particles
per mL) were injected via a tail vein 1 week in advance of Dox
treatment, which then continued for a further 2 weeks.
ELISA
Tracheas were homogenized and underwent enzyme-linked
immunosorbent assay (ELISA) for their concentration of
hIL-1b with the use of a kit (DY201, R&D Systems, Min-
neapolis, MN) according to the manufacturer’s instructions
as described previously.5 The assay has a detection range of
4 to 250 pg/mL and no cross-reactivity to mouse IL-1b. hIL-
1b concentrations were normalized to the total tracheal
protein concentration, as measured with the bicinchoninic
acid method (Sigma-Aldrich).
Tissue Preparation and Immunohistochemistry
The vasculature was perfused transcardially for 2 minutes
with 1% paraformaldehyde in PBS, pH 7.4. Tissues were
then immersed in ﬁxative for 1 hour at 4C, washed, and
stained immunohistochemically by incubating whole mounts
or sections with one or more of the following primary anti-
bodies (Table 1) diluted at 1 mg/mL as described previously. 22
We stained macrophages and dendritic cells with the use of an
antibody to allograft inﬂammatory factor 1, also known as Iba1,
ionized calcium binding adapter molecule 1 (Aif1/Iba1),33 and
neutrophils with S100A8 (also known as MRP8 or calgranulin
A34), because these antibodies worked well on ﬁxed wholeTable 1 Antibodies Used in Present Study
Target Supplier
LYVE-1 AngioBio (Del Mar, CA)
PECAM-1/CD31 Thermo/Fisher (Pittsburgh, PA)
ZO-1 Invitrogen/Zymed (Grand Island, NY)
S100A8 R&D Systems
Aif1/Iba1 Wako Chemicals (Richmond, VA)
VEGF-C Santa Cruz Biotechnology (Dallas, TX)
IL1R1 R&D Systems
PGP9.5 Ultraclone (Yarmouth, UK)
Keratin 5 Dr. Julia A. Segre
Pan-cytokeratin Dako (Carpinteria, CA)
CD45 BD Biosciences (San Jose, CA)
1436mount preparations. Airway epithelial cells were identiﬁed by
staining with antibodies to pan-cytokeratin or keratin 5, and
neuroendocrine cells were stained for Protein Gene Product
9.5 (PGP9.5). Secondary antibodies were labeled with ﬂuo-
rescein isothiocyanate, Alexa dyes, cyanine 3, or cyanine 5
(Jackson ImmunoResearch Laboratories Inc.,West Grove, PA).
Specimens were imaged with a Zeiss LSM-510 confocal
microscope (Carl Zeiss, Thornwood, NY) with the use of AIM
software version 4.0 (Carl Zeiss). Bronchial lymph nodes were
weighed to assess the extent of immune activation in the
respiratory tract.
Morphometric Measurements
Vessel diameter and length, width, and mucosal area
occupied by blood vessels and lymphatics were measured in
real-time images of tracheas stained for platelet endothelial
cell adhesion molecule (PECAM)-1 and lymphatic endo-
thelial hyaluronan receptor (LYVE)-1 by using a digitizing
tablet linked to a video camera on a Zeiss Axiophot
microscope with 10/0.5 NA, 20/0.75 NA, or 40/1.0
NA objectives as described previously.22 Area densities for
blood vessels and lymphatics are presented for regions of
the mucosa overlying the tracheal cartilage rings, because
these regions experienced the greatest lymphangiogenesis
and most noticeable changes.
Gene Expression Proﬁling
We assessed the expression of selected genes in tracheas of
three bi-transgenic CCSP/IL-1b mice and three single-
transgenic control CCSP mice immediately after 2 weeks of
Dox exposure (Dox-On) or 2 weeks after the end of Dox
exposure (Dox-On/Dox-Off). Total RNA was isolated as
described.5 For gene array experiments, 300 ng of total RNA
extracted from each trachea was ampliﬁed, transcribed to
complementary RNA, and biotinylatedwith an Illumina Total
Prep RNA Ampliﬁcation kit (Ambion, Austin, TX). RNA
concentrations and qualitywas checkedwith aNanodropND-
1000 spectrophotometer (Bio-Rad, Hercules, CA) and an
Experion electrophoresis station (Bio-Rad). For each sample,
1500 ng of complementary RNA was hybridized to SentrixCatalog No. Species Clone
11-034 Rabbit Polyclonal
MA3105 Armenian hamster 2H8
61-7300 Rabbit Polyclonal
AF3059 Goat Polyclonal
019-19741 Rabbit Polyclonal
sc-7132 Goat Polyclonal
AF771 Goat Polyclonal
RA95101 Rabbit Polyclonal
N/A Rabbit Polyclonal
Z0622 Rabbit Polyclonal
550539 Rat 30-F11
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Figure 1 Distribution of Clara cells in mouse tracheal epithelium. Confocal
images of whole mount of trachea from pathogen-free CCSP/EGFP mouse given
Dox for 2 days. A: Green ﬂuorescent nuclei of Clara cells are more abundant in
regions of epithelium between cartilages than over cartilages. Blood vessels
(PECAM-1, cyan) and lymphatics (LYVE-1, red) form segmented networks
between the cartilage rings.B: Some epithelial cells outlinedbyborders stained
with tight junction protein ZO-1 (red) have green ﬂuorescent nuclei repre-
senting CCSP/EGFP (green). Scale bars: 200 mm (A); 50 mm (B).
Figure 2 Concentration of IL-1b in trachea after transgenic over-
expression in tracheas of CCSP/IL-b mice. ELISA measurements of hIL-1b in
bi-transgenic CCSP/IL-1b mice and in control single-transgenic CCSP mice
after exposure to Dox. hIL-1b level is signiﬁcantly lower at 4 weeks of Dox
than at 2 weeks and undetectable in control mice and in bi-transgenic mice
given Dox for 2 weeks, then normal water for 2 weeks. Values normalized to
total protein concentration. Values in single-transgenic mice were at zero.
Note break in y axis; n Z 4 to 6 mice/group.
IL-1b Induces LymphangiogenesisMouse WG-6 v2 Expression Bead Chips (Illumina, San
Diego, CA) at 58C overnight according to the manufac-
turer’s instructions. Gene chips were scanned with Illumina
BeadArray Reader, and numerical results were extractedwith
GenomeStudio software version 1.6.0 (Illumina).
Statistical Analysis
Data are presented as means  SEMs with four to ﬁve mice
per group unless otherwise indicated. Differences betweenThe American Journal of Pathology - ajp.amjpathol.orgmeans were assessed by analysis of variance followed
by Dunn-Bonferroni test for multiple comparisons, and
P values <0.05 were considered signiﬁcant. For gene exp-
ression studies, data were analyzed by the Limma package
of BioConductor software version 2.6 and expressed as fold
changes between groups. Adjusted P values were calculated
and corrected to adjust for false discovery rates in large
samples.
Results
Distribution and Amount of Transgenic IL-1b in
Tracheal Epithelium
To understand the distribution of the sources of IL-1b
production in tracheas of bi-transgenic CCSP/IL-1bmice, we
ﬁrst examined Clara cells in bi-transgenic CCSP/EGFP mice.
These mice express nuclear-targeted GFP wherever CCSP-
rtTA promoters are activated by Dox (Figure 1A). Numerous
strongly ﬂuorescent nuclei were present in the epithelium, as
recognized by cell borders stained for ZO-1 (Figure 1B).
Triple antibody-labeling experiments showed that the great-
est density of Clara cells with ﬂuorescent GFP nuclei was in
the epithelium overlying the intercartilage regions. The
mucosa between cartilages contained most of the lymphatic
vessels stained for LYVE-1 and blood vessels stained for
PECAM-1. Regions of mucosa over the cartilages were
almost completely free of lymphatic vessels (Figure 1A).
However, a few Clara cells with ﬂuorescent nuclei were also
found over the cartilages (Figure 1, A and B).
To examine the time course and amount of the transgene
expression in mouse tracheas, we assayed hIL-1b by ELISA
(Figure 2). Twoweeks after induction of transgene activity by
exposure to Dox, CCSP/IL-1bmouse tracheas had 168 pg of
hIL-1b/mg of total protein. Four weeks after continuous Dox1437
Figure 3 Effect of IL-1b expression on lymphatics and blood vessels. AeF: Whole mounts of tracheas from bi-transgenic CCSP/IL-1b mice stained for lymphatics
(LYVE-1, red) and blood vessels (PECAM-1, green).Boxed areas located inA,B, and C are enlarged inD, E, and F.A andD: Baseline (normal water, no Dox).B and E: Two
weeks afterDox (Dox-On).CandF: After 2weeksofDox, then2weeksof normalwater (Dox-On/Off).GeI: Quantitation of lymphatic areadensity (G) andblood vessel area
density (H), bothmeasured over cartilage regions andweights of draining bronchial lymphnodes (I). Lymphatics grow after Dox but donot regress after cessation of Dox.
Nochangedetected inbloodvessels. *P< 0.05, single-transgenicmiceormicenotgivenDox. yP< 0.05,micegivenDox for 2weeks. Four ormoremicepergroup. JandK:
Tracheal whole mounts from CCSP/IL-1b mice treated in advance with either a control adeno-associated null virus (AAV-null; J) or AAV-soluble VEGFR-3 (K) to absorb
VEGFR-3 ligands then treated for 2 week with Dox to induce overexpression of IL-1b. Lymphatics were stained for LYVE-1 (red) and blood vessels for PECAM-1 (green). L:
Quantitation of lymphatic area density over cartilage rings. *P< 0.05, mice not given Dox. Five or more mice per group. Scale bars: 200 mm (A); 50 mm (D and J).
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Figure 4 Effect of IL-1b expression on leukocytes in trachea of CCSP/IL-1bmice. AeC: Whole mounts of tracheas stained for macrophages/dendritic cells (Aif1/
Iba1, red) and neutrophils (S100A8, green).A: At baseline (no Dox), few leukocytes stain for AIf1/Iba1, but some (arrows) have clear dendriticmorphology. Scale bar
Z 50 mm. B: Large increase in leukocytes stained for S100A8 (green) and Aif1/Iba1 (red), mostly with rounded phenotype (arrowheads) at 2 weeks of Dox. C:
Reduction in leukocyte number after 2 weeks of Dox, followed by 2 weeks of normal water. Cells staining for Aif1/Iba1 and with dendritic morphology re-appear
(arrows). DeI: Staining for macrophages/dendritic cells (red) and VEGF-C (green) in single- or double-transgenic mice given Dox for 2 weeks. Diffuse granular
staining with the polyclonal antibody to VEGF-C was found in the epithelium of all tracheas. DeF: Single-transgenic CCSP mice. D: Many cells staining for Aif1/Iba1
have a dendritic morphology E: Only a few (arrow) have weak staining for VEGF-C (arrow). F: Merged image. GeI: Double-transgenic CCSP/IL-1bmice. G: Most cells
staining for Aif1/Iba1 have a rounded macrophage-like phenotype. H: Some of these macrophages have stronger VEGF-C staining (arrowheads). I: Merged image.
IL-1b Induces Lymphangiogenesisexposure, levels of hIL-1b were signiﬁcantly lower in
tracheas of bi-transgenic mice (only 9 pg/mg of total protein)
than after a 2-week exposure. In Dox-On/Dox-Off reversal
experiments, 2 weeks after removal of Dox after a 2-week
exposure, hIL-1b levels dropped to baseline levels. hIL-1b
was undetectable in tracheas of single-transgenic CCSPmice.
Induction of Lymphatic Growth by IL-1b
Overexpression
Tracheal lymphatics formed a regular stereotyped segmen-
tally repeated network of vessels in CCSP/IL-1b miceThe American Journal of Pathology - ajp.amjpathol.org(Figure 3A) under baseline conditions (normal water), and in
control single-transgenic CCSP mice exposed to Dox (not
shown). These vessels closely resembled normal lymphatics
in wild-type mice. Almost all of the lymphatics were conﬁned
to the regions of mucosa located between the cartilage rings.
One week after transgene induction by exposure to Dox, no
obvious differences were found between control and CCSP/
IL-1b groups (not shown). However, after 2 weeks of Dox,
numerous lymphatic sprouts were present over the cartilages
(Figure 3B). The proﬁles of these new lymphatic sprouts were
generally smooth in outline and were smaller in diameter than
their parent lymphatics (19.4 0.5 mmversus 51.0 3.1 mm;1439
Table 2 Effect of IL-1b Overexpression in Mouse Trachea on Expression of Selected Genes for Chemokines and Their Receptors, Leukocyte-
Related Genes, Extracellular Matrix Proteases, Inﬂammation-Related Genes, and Lymphatic Markers
Symbol Name Fold change* Adjusted P valuey
Chemokines and receptors
Cxcl1 Chemokine (C-X-C motif) ligand 1 20.80 0.00009
Ccl7 Chemokine (C-C motif) ligand 7 7.06 0.00008
Ccl17 Chemokine (C-C motif) ligand 17 4.91 0.00036
Ccl9 Chemokine (C-C motif) ligand 9 4.76 0.00001
Cxcr2/Il8r1 Chemokine (C-X-C motif) receptor 2 3.57 0.00190
Cxcl14 Chemokine (C-X-C motif) ligand 14 3.07 0.00004
Ccr6 Chemokine (C-C motif) receptor 6 3.01 0.00001
Cxcl16 Chemokine (C-X-C motif) ligand 16 2.53 0.00001
Leukocyte related
Lcn2 Lipocalin 2 (neutrophil-gelatinase associated lipocalin) 37.81 5.67108
S100a9 S100 calcium binding protein A9 (calgranulin B) 14.46 0.00002
S100a8 S100 calcium binding protein A8 (calgranulin A) 6.65 0.00051
Ncf4 Neutrophil cytosolic factor 4 6.08 5.42106
Selp P-selectin 5.14 0.00037
Selplg P-selectin ligand 4.62 4.75106
Aif1 Allograft inflammatory factor 1 (Aif1/Iba1) 4.36 0.00001
Cd68 CD68 antigen 2.98 0.00009
Extracellular matrix proteases
(remodeling related)
Mmp3 Matrix metallopeptidase 3 (stromelysin, progelatinase) 8.90 0.00012
Ctse Cathepsin E 3.86 0.00079
Mmp12 Matrix metallopeptidase 12 2.79 0.00460
Inﬂammation and asthma related
Clca3 Chloride channel calcium activated 3 61.91 4.85105
Chi3l4 Chitinase 3-like 4 42.46 6.39107
Saa3 Serum amyloid A3 34.57 1.73106
Chi3l1 Chitinase 3-like 1 16.19 2.13105
Muc5ac Mucin 5, subtypes A and C, tracheobronchial/gastric 13.18 1.25106
Muc13 Mucin 13 11.03 7.82107
Clca4 Chloride channel calcium activated 4 10.74 3.65106
Interleukin 1 related
Il1b Interleukin 1 beta (mouse gene) 11.52 0.00002
Il1rn Interleukin 1 receptor antagonist 4.86 0.00001
Il1r2 Interleukin 1 receptor, type II 3.09 0.00005
TNF family related
Ltb Lymphotoxin-beta 7.32 0.00002
Tnf Tumor necrosis factor alpha 3.50 0.00005
Lta Lymphotoxin-alpha 2.10 0.00377
Gene expression in tracheas of bi-transgenic CCSP/IL-1b mice given Dox for 2 weeks as determined by Illumina genome-wide gene array chips; nZ 3 mice
per group.
*Fold changes compared with control bi-transgenic mice given normal water.
yP values adjusted to compensate for false discovery rate in large microarray samples.
Baluk et alP< 0.05). The newly formed lymphatics persisted for at least
2 weeks after the cessation of Dox (see Reversability of
Lymphatic Growth, Lymph Node Hypertrophy, Leukocyte
Inﬂux, and Gene Expression and Figure 3C).
Lack of Airway Blood Vessel Growth after IL-1b
Overexpression
Under the same conditions as above, we could not detect
any obvious differences in the network of blood vessels
(Figure 3, DeF). The visual impressions of a large increase
in lymphatics but no change in blood vessels were1440conﬁrmed statistically bymeasurements of vessel area density
made over the tracheal cartilages (Figure 3, G and H).
Lymph Node Hypertrophy and Leukocyte Inﬂux by
IL-1b Overexpression
In addition to the changes in lymphatic vessels noted above,
IL-1b transgene expression induced an immune response and
caused the bronchial lymph nodes that drain the trachea and
lungs to hypertrophy. Compared with baseline values, the
bronchial lymph nodeweights of CCSP/IL-1bmice increased
more than sixfold after 2 weeks of exposure to Doxajp.amjpathol.org - The American Journal of Pathology
Figure 5 Lack of effect of deletion of CXCR2
receptors on changes in lymphatics and blood
vessels induced by IL-1b overexpression. Tracheal
whole mounts from CCSP/IL-1b bi-transgenic mice
(A) and CCSP/IL-1b/CXCR2/ triple-transgenic
mice (B) given Dox for 4 weeks, then stained to
detect neutrophils by their S100A8 immunoreac-
tivity (green). C: Neutrophil numbers were 93%
lower in CXCR2/ mice than in CXCR2þ/þ mice. *P
< 0.05. CCSP/IL-1b bi-transgenic mice (D) and
CCSP/IL-1b/CXCR2/ triple-transgenic mice (E)
were given Dox for 4 weeks. Lymphatics (LYVE-1,
red) and blood vessels (PECAM-1, green) and were
stained and quantiﬁed (F and G). Lymphangio-
genesis (arrows) was equally abundant in both
groups of mice given Dox (*P < 0.05 compared
with mice lacking the IL-1b transgene) and was not
signiﬁcantly different between mice with or
without CXCR2 receptors. No obvious changes were
found in blood vessels. Four to six mice per group.
Scale bars: 50 mm (A); 200 mm (D).
IL-1b Induces Lymphangiogenesis(Figure 3I). However, after 4 weeks of continuous exposure,
the increase was signiﬁcantly less (only approximately four-
fold). Lymph nodes were still enlarged (approximately
threefold) in CCSP/IL-1b mice exposed to Dox for 2 weeks
followed by 2 weeks of normal water (Figure 3I).
Mechanism of Lymphangiogenesis after IL-1b
Overexpression
In many inﬂammatory situations, the growth of new lymphatic
vessels is mediated by the ligands VEGF-C or VEGF-D
signaling via VEGFR-3 receptors located on existing
lymphatics.35 To determine whether this was also the case in
the presentmodel of IL-1b overexpression in adult airways, we
absorbed VEGFR-3 ligands with an excess of AAV-mediated
soluble VEGFR-3 receptor, given systemically 1 week in
advance of a 2-week overexpression of IL-1b. In mice treated
with control AAV-null, IL-1b overexpression inducedThe American Journal of Pathology - ajp.amjpathol.orglymphatic growth in the mucosa over the tracheal cartilage
rings (Figure 3J), but it did not induce any lymphangiogenesis
in mice treated with soluble VEGFR-3 (Figure 3, K and L).
Because IL-1b overexpression induces an inﬂux of imm-
une cells into the lungs, in particular neutrophils and mac-
rophages,8,29 we assessed whether a similar phenomenon
occurs in the airways. Two populations of endogenous
macrophages and dendritic cells immunohistochemically
stained for Aif1/Iba1 were present under baseline conditions
(Figure 4A). Dendritic cells with long slender process were
located just below the tracheal epithelium, and larger, fatter
macrophages with shorter processes were found in deeper
layers of the tracheal mucosa, as determined by focusing up
and down. In contrast, neutrophils stained for S100A8 were
scarce. In our preparations, staining for Aif1/Iba1 and
S100A8 was not colocalized in the same inﬂammatory cells;
that is, these markers labeled separate populations of
macrophages/dendritic cells and neutrophils. Two weeks1441
Figure 6 Persistence of newly formed lymphatics in trachea of CCSP/IL-
1b bi-transgenic mouse after cessation of stimulus. Tracheal whole mount
after 2 weeks of Dox, followed by 2 weeks of normal water. High magni-
ﬁcation view of trachea treated similarly to that shown in Figure 3F. A:
Some endothelial cells (arrowheads) in a few lymphatics have much weaker
LYVE-1 staining (red) than other lymphatic endothelial cells. Their borders
are demarcated by PECAM-1 (green). Blood vessels (arrowheads) have
stronger PECAM-1 staining but no LYVE-1. B. White box in A is enlarged.
Some endothelial cells in this isolated lymphatic island have a nonuniform
distribution of LYVE-1 (red), including dense granular regions and irregular
membrane protrusions (arrowheads) and intense PECAM-1 staining
(arrows). Scale bars: 200 mm (A); 50 mm (B).
Baluk et alafter exposure of CCSP/IL-1b mice to Dox, the number of
neutrophils and rounded macrophages was greatly increased,
but the number of dendritic cells with long elaborate
processes near the epithelium appeared to be decreased
(Figure 4B). Two weeks after the withdrawal of Dox, the
number and appearance of macrophages/dendritic cells and
neutrophils returned almost to baseline (Figure 4C).
To determine whether the macrophages were a potential
source of VEGF-C, we examined the distribution of Aif1/
Iba1þ macrophages/dendritic cells and VEGF-C immuno-
reactivity in tracheas of double-transgenic CCSP/IL-1b mice
after Dox treatment for 2 weeks (Figure 4, DeI). In single-
transgenic CCSP mice used as controls, VEGF-C immuno-
reactivity was weak and granular in some epithelial cells that
resembled dendritic cells (Figure 4, DeF). In double-
transgenic CCSP/IL-1b mice, VEGF-C immunoreactivity
was strong in some Aif1/Iba1þ cells in the lamina propria but
was weak and granular in epithelial cells (Figure 4, GeI).
Effect of IL-1b Overexpression on Gene Expression
IL-1b overexpression has been shown to up-regulate the
expression of inﬂammatory genes in the developing mouse
lungs.8,29Wewanted to determinewhether similar geneswere
up-regulated in the tracheas of adult mice. As expected, IL-1b
up-regulated many genes for chemokines and their receptors
(Table 2). For example, the neutrophil chemoattractant che-
mokine Cxcl1 was up-regulated 20.8-fold, as were other
markers of inﬂammation (eg, serum amyloid A3, 34.6-fold),
genes associated with neutrophils (S100a8 and S100a9; 6.7
and 14.5-fold, respectively), macrophages (Aif1/Iba1; 4.4-
fold), other genes related to leukocyte-related genes, and
genes up-regulated in asthma (Muc5ac). Genes for mouse
IL-1b, tumor necrosis factor a (TNFa), and lymphotoxin-b
were up-regulated (11.5-, 3.5-, and 7.3-fold, respectively).1442Lack of Dependence of Lymphatic Growth on
Neutrophil Inﬂux
Because overexpression of IL-1b recruits neutrophils, we
sought to examine whether their recruitment was essential for
the lymphangiogenesis. In mice, CXCR2 receptors (also
known as IL8R1) are the dominant receptors responsible for
chemotaxis of neutrophils to sites of inﬂammation.28 We
cross-bredCXCR2/mice to bi-transgenicCCSP/IL-1bmice
to generate triple-transgenic mice29 and examined whether
lymphangiogenesis differed between wild-type CCSP/IL-1b
and the triple-transgenic CCSP/IL-1b/CXCR2/ mice after
IL-1b overexpression (Figure 5). Tracheas stained for the
neutrophil marker S100A8 showed that CXCR2/ mice had
93% fewer neutrophils in the mucosa over cartilage rings
(Figure 5, AeC). We found that after Dox treatment, the
increased area density of lymphatics was not signiﬁcantly
different in CCSP/IL-1b and triple-transgenic CCSP/IL-1b/
CXCR2/mice (Figure 5, D and E). Furthermore, the lack of
CXCR2 receptors had no effect of lymphatics in baseline
conditions or on blood vessels in any conditions examined
(Figure 5, F and G).
Reversibility of Lymphatic Growth, Lymph Node
Hypertrophy, Leukocyte Inﬂux, and Gene Expression
To determine whether the effects of IL-1b transgene over-
expression described above could be reversed, we examined
CCSP/IL-1b mice that had been exposed to Dox for 2 weeks
and then given normal water for 2 weeks (Dox-On/Dox-Off).
A striking ﬁnding, already noted above (Figure 3, C, F, and
G), was that the extent of lymphatic proliferation was largely
unchanged after the cessation of Dox. When examined more
closely by high-magniﬁcation confocal microscopy, a few
lymphatics showed abnormal features that suggested degen-
eration and regression. Such lymphatics had some endothelial
cells with much weaker LYVE-1 staining than the rest
(Figure 6A). Occasional segments appeared as isolated
“islands” with a nonuniform distribution of LYVE-1 and
PECAM-1, including particularly dense regions (Figure 6B).
Additional experiments with CCSP/IL-1b mice exposed
to Dox for 4 weeks and then given normal water showed
that newly formed lymphatics lasted up to 13 weeks
(Supplemental Figure S1).
Blood vessels appeared normal in Dox-On/Dox-Off
conditions (Figure 3, C, F, and H, and Figure 6). In
contrast to the persistence of newly formed lymphatics,
bronchial lymph node weights and the inﬂux of macro-
phages and neutrophils were reduced toward baseline values
in Dox-On/Dox-Off experiments (Figures 3H and 4C).
IL1R1 Receptor Localization in Mouse Trachea and
Other Tissues
In an effort to gain insight into the mechanism by which
IL-1b overexpression induces lymphangiogenesis, weajp.amjpathol.org - The American Journal of Pathology
Figure 7 IL1R1 receptor immunoreactivity in
tracheas of wild-type mice. A: Low magniﬁcation
confocal image of IL1R1 receptors (red), lymphatics
(LYVE-1, green), and blood vessels (PECAM-1, cyan)
in whole mount of trachea. White box is enlarged in
BeE. B: Two types of epithelial cells stain for
IL1R1 (red). Clustered polygonal cells stain weakly
(arrows), and scattered elongated spindle-shaped
cells stain strongly (arrowheads). CeE: Structures
corresponding to lymphatics (green) or blood
vessels (blue) have no detectable IL1R1 receptor
staining. FeH: The elongated spindle-shaped cells
(arrowheads) with strong red IL-RI staining (F)
correspond to neuroendocrine cells (G) that also
stain for protein gene product 9.5 (PGP9.5, green),
also found in some ﬁne varicose unmyelinated
nerve ﬁbers. H: Merged image. IeK: The clusters of
polygonal cells (I) that stain weakly (arrows) for
IL1R1 (red) correspond to a subset of a larger
number (J) of epithelial basal cells that express
keratin 5 (green). K: Merged image. Scale bars:
200 mm (A); 50 mm (B and F).
IL-1b Induces Lymphangiogenesissought to identify the target cells with the most abundant
IL1R1 receptors, which are believed to be the only functional
receptors for IL-1b (and IL-1a). We stained whole mounts of
wild-type mouse tracheas for IL1R1 immunoreactivity and
counterstained lymphatic vessels for LYVE-1 and blood
vessels for PECAM-1. Two types of cells in the epithelium
had IL1R1 immunoreactivity (Figure 7A). Scattered elon-
gated cells stained strongly, and clusters of polygonal cells
had weaker staining (Figure 7B). These cells were most
abundant in the epithelium between cartilage rings, but some
were present over the cartilages. Lymphatics (Figure 7C) and
blood vessels (Figure 7D) or, for that matter, all other kinds of
cells in the trachea had no detectable IL1R1 immunoreac-
tivity (Figure 7E).
To identify the epithelial cells with IL1R1 immunoreac-
tivity, we asked whether it was found in neuroendocrine
cells, visualized by PGP9.5, or in basal cells, visualized by
keratin 5. IL1R1 immunoreactivity was strong in many
neuroendocrine cells (Figure 7, FeH) and was moderate in
some groups of basal cells stained for keratin 5 in the
tracheal epithelium (Figure 7, IeK). Little IL1R1 immu-
noreactivity was found in other cell types in the trachea.The American Journal of Pathology - ajp.amjpathol.orgThe identity of IL1R1 immunoreactive cells was
conﬁrmed in histologic sections of trachea, and the speci-
ﬁcity of the antibody to mouse IL1R1 was tested in brain
and heart. IL1R1 immunoreactivity colocalized with pan-
cytokeratin in some epithelial cells of the trachea but was
not found in blood vessel or lymphatic endothelial cells or
other cells in the trachea, including CD45-immunoreactive
leukocytes (Supplemental Figure S2, AeD). In contrast to
the trachea, IL1R1 immunoreactivity colocalized with
PECAM-1 in some blood vessels in the brain and heart
(Supplemental Figure S2 EeJ). No IL1R1 staining was
found in experiments in which the primary antibody was
omitted or replaced by normal goat IgG (data not shown).Discussion
In this study we sought to determine the effects of inducible,
selective overexpression of IL-1b on blood vessels and
lymphatics in the airways and the reversibility of these
effects. By using CCSP/IL-1b double-transgenic mice, we
found that overexpression of hIL-1b in the mouse trachea1443
Baluk et alinduced lymphangiogenesis without accompanying angio-
genesis. The lymphangiogenesis was found to require VEGF-
C and/or VEGF-D ligands that drive VEGFR-3 signaling.
Overexpression of IL-1b also induced the inﬂux of neutro-
phils and macrophages into the airways. Some macrophages
contained VEGF-C, which drives lymphatic growth, but
neutrophil inﬂuxwas not essential for the lymphangiogenesis.
The newly formed lymphatics persisted in the airways for
several weeks after IL-1b overexpression was ended by
withdrawal of Dox, but other changes returned to baseline.
Growth of Lymphatics and Presumptive Mechanism
IL-1beinduced lymphangiogenesis is likely to involve
VEGF-C- or VEGF-D-mediated signaling of VEGFR-3,35
but site of action of IL-1b and the source of the VEGF-C/D
had not been identiﬁed. We found that lymphangiogenesis in
CCSP/IL-1b mice was completely prevented by sequestration
of ligands that bind VEGFR-3. In search of the source of the
ligands, we found VEGF-C immunoreactivity in some Aif1/
Iba1þ macrophages in the trachea.
IL1R1 immunoreactivity was strong in some airway
epithelial cells but not in lymphatics or blood vessels. The
absence of IL1R1 immunoreactivity does not ensure the
absence of the receptor, and only a few copies of receptor per
cell can effectively mediate IL-1 signaling.36 However, the
detection of IL1R1 immunoreactivity on epithelial basal cells
and neuroendocrine cells of the trachea and on blood vessels in
thebrain andheart,whichare known to respond to IL-1b,weigh
against lymphatics as the main target of IL-1b in the trachea.
A possible alternative mechanism of lymphangiogenesis
involves IL-1b activation of IL1R1-positive epithelial cells to
release chemokines that then attract leukocytes that secrete
lymphangiogenic factors.Macrophages have been reported to
contain VEGF-C and neutrophils to contain VEGF-D.21,35
We asked whether neutrophils are responsible for lym-
phangiogenesis in CCSP/IL-1b mice, because these cells are
thought to mediate lung remodeling after IL-1b over-
expression in a model of bronchopulmonary dysplasia in
infant mice.29 We found that lymphangiogenesis was not
signiﬁcantly different after IL-1b overexpression inCXCR2/
mice, which lack the dominant pathway for neutrophil recruit-
ment.28,37 This ﬁnding indicates that neutrophils are not essen-
tial for lymphangiogenesis in these mice and focuses attention
on macrophages that produce VEGF-C.
Further workwill be required to understand the link between
IL-1b secretion and action in the epithelium and macrophage
productionofVEGF-C.According toone possiblemechanism,
epithelial basal cells and/or neuroendocrine cells activated by
IL-1b secrete chemokines that attract the macrophages. Recent
studies of basal cells isolated from mouse tracheas have re-
ported a distinct gene expression proﬁle38 that could give
insight into the signaling pathways involved.
Another notable ﬁnding in the present study was the
persistence of many new lymphatics after withdrawal of the
Dox that drove IL-1b overexpression. Most other features1444accompanying IL-1b overexpression, including IL-1b
mRNA expression in the trachea and number of recruited
leukocytes and lymph node hypertrophy, returned to base-
line after Dox was withdrawn. Some new lymphatics that
appeared to undergo regression had little or no LYVE-1
immunoreactivity and were fragmented.
The persistence of the newly formed lymphaticsmirrors that
of lymphatics that grow in tracheas of mice afterM. pulmonis
bacterial infection, despite treatment with antibiotics or
dexamethasone.17,21 Newly formed lymphatics also persist for
many weeks in skin of transgenic mice after the over-
expression of VEGF-C that drives the lymphangiogenesis.39
Similarly, persistence of abnormally numerous lymphatics
has been reported in the skin of patients with breast cancer
more than a year after radiation therapy.40
Persistence of new lymphatics after the stimulus is with-
drawn contrasts with the rapid regression of angiogenic blood
vessels after inhibition of VEGF-A. Pericytes and well-
developed basement membrane are thought to contribute to
the stabilization of blood vessels, but lymphatic vessels have
neither.
Absence of Angiogenesis
Inﬂammation and angiogenesis often go together, but not
always. IL-1b increases in inﬂammation and is well known to
trigger the activation of inﬂammatory genes and proteins.1,41
In addition, IL-1b has been reported to down-regulate angio-
poietin-1, which can favor blood vessel destabilization and
angiogenesis.11Therefore, contrary toour expectations,wewere
surprised to ﬁnd that overexpression of hIL-1b in CCSP/IL-1b
mice did not induce angiogenesis or blood vessel remodeling in
the mouse trachea, despite clear signs of inﬂammation, as re-
ﬂected by leukocyte inﬂux and gene expression changes.
In the eye and in tumors, whereby IL-1b and angiogenesis
can increase in parallel, most evidence suggests that the
angiogenesis is linked to the recruitment of leukocytes and
their production of VEGF and other growth factors.23,42e44 In
these tissues, inhibition of IL-1b production or receptor
signaling can reduce or prevent angiogenesis, presumably by
reducing the inﬂux of inﬂammatory cells.10,12,13,23 Why the
recruited leukocytes did not promote angiogenesis in the
trachea of CCSP/IL-1b mice is puzzling and deserves further
study. The observation of robust expression of inﬂammation-
related genes such as serum amyloid A3 weighs against the
possibility that IL-1b in the airways did not reach the threshold
required to promote angiogenesis, but this cannot be excluded.
Attributes and Limitations of the Tracheal Model
The present studies evolved from previous studies of trans-
genic overexpression of IL-1b in the mouse lung and from
studies of the tracheal vasculature of mice with respiratory
tract infections. IL-1b overexpression causes pulmonary
inﬂammation, emphysema, and airway remodeling in the
adult mouse lung4 and pulmonary dysplasia in neonatalajp.amjpathol.org - The American Journal of Pathology
IL-1b Induces Lymphangiogenesislungs.5,8,29,45 Studies of the lung also showed that hIL-1b
concentrations rapidly returned to baseline levels after
cessation of Dox, indicative of a sharp off-response. Our
earlier studies of tracheas in mice withM. pulmonis infection
showed robust lymphangiogenesis and blood vessel remod-
eling and up-regulation of many inﬂammatory genes, some
overlapping those found in the present study, including IL-
1b.17,20 The present model permitted us to study the effects of
IL-1b on the airway vasculature in a regulated and reversible
fashion without the complications of bacterial infection.
The mouse trachea has several experimental advantages
over the lungs for studies of the vasculature. Blood vessels
and lymphatics are arranged in a regular two-dimensional
plexus observable in its entirety. The vascular architecture is
simpler than in the lung, facilitating the relation of vessel
changes to the levels of IL-1b. The trachea can display several
distinct patterns of vascular changes, including angiogenesis,
vascular remodeling, and lymphangiogenesis, depending on
the nature of the stimulus.21,46 For instance, transgenic
overexpression of VEGF-A causes angiogenesis, but not
lymphangiogenesis, exactly the opposite phenomenon than
after IL-1b overexpression.47 The sensitivity and versatility of
mouse tracheal whole-mount preparations for visualizing the
vasculature makes it likely that angiogenesis would have
detected had it occurred after IL-1b overexpression.
In the trachea, the degree of IL-1b overexpression was
similar to that found previously in the lungs.4 Gene proﬁling
also showed that mouse IL-1b was up-regulated. Our
immunohistochemical and ELISA results conﬁrmed that
tracheal Clara cells are sufﬁciently abundant to drive robust
transgene overexpression via their Dox-regulated CCSP
promoters.48,49 We also found that IL-1b levels were
signiﬁcantly lower at 4 weeks than at 2 weeks of continuous
Dox exposure, perhaps suggesting an immune response to
hIL-1b protein. Overall, our gene expression studies sup-
ported our immunohistochemical studies and were broadly
consistent with the up-regulated genes reported in the lungs
after overexpression of IL-1b, including several chemokines
and leukocyte markers.29 Consistent with previous notions
that IL-1b stimulated its own production in a feedback
loop,36 we found that transgenic overexpression of hIL-1b
in mouse trachea up-regulated mouse IL-1b, and also TNFa
and lymphotoxin-b. Interestingly, both IL-1b and TNFa are
known to up-regulate VEGF-C gene expression in vitro.24
Consistently, our ﬁnding that the lymphangiogenesis
induced by IL-1b was completely blocked by soluble
VEGFR-3 also provides strong evidence for VEGFR-3
signaling in driving the lymphatic growth.
Our ﬁndings of effects of IL-1b overexpression in the
trachea of CCSP/IL-1b transgenic mice differ in several key
respects from those of studies of corneal implants containing
VEGF, VEGF-C, ﬁbroblast growth factor-2, or other growth
factors.23,50,51 These factors all induce angiogenesis and
lymphangiogenesis, but to different extents. The reasons for
the different results in the trachea are not clear but could
involve multiple issues, including differences in the route ofThe American Journal of Pathology - ajp.amjpathol.orgadministration and local concentrations of mediators, time
course and threshold of inﬂammatory effects, and cellular
composition of cornea and trachea. The differences between
the effects of IL-1b on the vasculature of the cornea and
trachea suggest that examination of other tissues is warranted.
Another issue for consideration is that IL-1b acts differently in
organs such as the heart and brain where the vasculature has
clear IL1R1 immunoreactivity. Therefore, it is premature to
generalize the present ﬁndings to other organs.
In summary, we found that overexpression of hIL-1b in
mouse airways resulted in lymphangiogenesis, driven by
VEGFR-3 signaling, but not angiogenesis. The newly
formed lymphatics persisted long after IL-1b overexpression
was switched off. In addition, IL-1b overexpression induced
the inﬂux of neutrophils and macrophages; hypertrophy of
draining lymph nodes; and up-regulation of genes for che-
mokines, leukocyte markers, and some molecules associated
with allergic inﬂammation. Neutrophil inﬂux was not
essential for IL-1b-induced lymphangiogenesis. The strong
staining for IL1R1 receptor immunoreactivity on airway
epithelial cells, apparent absence on lymphatics, and pres-
ence of VEGF-C in some macrophages is consistent with an
indirect mechanism of IL-1beinduced lymphangiogenesis,
whereby IL1R1 signaling in epithelial cells leads to chemo-
kine recruitment of macrophages that release VEGF-C.
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